Lupin Secures FDA Nod for Generic Colonoscopy Prep Drug, Eyes $133M Market — Lupin Pharmaceuticals, Inc.

Event summary

Lupin received FDA approval for its generic version of Sutab® tablets, used for colon cleansing before colonoscopies.
The drug is bioequivalent to Azurity Pharmaceuticals' Sutab®, with Lupin as the exclusive first-to-file, granting 180-day generic exclusivity.
Lupin will manufacture the product at its Nagpur facility in India.
The reference drug (Sutab®) had estimated U.S. sales of $132.8 million (IQVIA MAT March 2026).

The big picture

Lupin's FDA approval strengthens its position in the U.S. generic drugs market, particularly in gastrointestinal therapies. The move aligns with broader industry trends of cost-effective alternatives to branded medications, as well as Lupin's strategy to expand its portfolio of complex generics. With a strong manufacturing footprint and global distribution network, Lupin is well-positioned to capitalize on this approval, though competition and regulatory dynamics remain key variables.

What we're watching

Market Penetration: How quickly Lupin can capture market share from Azurity Pharmaceuticals' Sutab® given its 180-day exclusivity.
Manufacturing Efficiency: Whether Lupin's Nagpur facility can scale production to meet U.S. demand without regulatory or operational hiccups.
Competitive Response: The likelihood of other generic drug manufacturers filing for approval once Lupin's exclusivity period ends.